Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Pharming Group N.V. clinical trials
The registry lists 26 studies whose lead sponsor is Pharming Group N.V. or one of 3 companies grouped under it. 3 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 19, 2026.
Keep track of what changes. Save the Pharming Group N.V. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Pharming Group N.V..
- Pharming Technologies B.V.22 studies →Subsidiary
Something wrong?
- 2 studies →
- NeuroVive Pharmaceutical AB2 studies →Acquired — became part of Pharming Group N.V., Feb 7, 2025 · source ↗
Something wrong?
Focus areas
Conditions Pharming Group N.V. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 26 of 26.
- Open Label Extension to Assess Long Term Safety and Efficacy of KL1333 in Patients With Primary Mitochondrial DiseaseRecruitingNCT07514338Phase 2
Sponsor listed in the registry: Pharming Technologies B.V.
- Efficacy of KL1333 in Adult Patients With Primary Mitochondrial DiseaseRecruitingNCT05650229Phase 2
Sponsor listed in the registry: Pharming Technologies B.V.
- An Open-Label Study to Assess the Safety & Efficacy of Leniolisib in Japanese Patients With APDSRecruitingNCT06249997Phase 3
Sponsor listed in the registry: Pharming Technologies B.V.
- Leniolisib for Immune Dysregulation in PIDsCompletedNCT06549114Phase 2
Sponsor listed in the registry: Pharming Technologies B.V.
- Leniolisib for Immune Dysregulation in CVIDCompletedNCT06897358Phase 2
Sponsor listed in the registry: Pharming Technologies B.V.
- Long-term Safety and Efficacy of Leniolisib in PIDs With Immune DysregulationActive, not recruitingNCT06990529Phase 2
Sponsor listed in the registry: Pharming Technologies B.V.
- Pediatric Patients Aged 1 to 6 Years With APDSActive, not recruitingNCT05693129Phase 3
Sponsor listed in the registry: Pharming Technologies B.V.
- Pediatric Patients Aged 4 to 11 Years With APDSActive, not recruitingNCT05438407Phase 3
Sponsor listed in the registry: Pharming Technologies B.V.
- Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLITerminatedNCT02859727Phase 2/3
Sponsor listed in the registry: Pharming Technologies B.V.
- C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) AttacksCompletedNCT01397864
Sponsor listed in the registry: Pharming Technologies B.V.
- Patient Registry to Evaluate the Real-world Safety of Ruconest®CompletedNCT03697187
Sponsor listed in the registry: Pharming Technologies B.V.
- Prevention of Acute Kidney Injury in Patients With NSTEMITerminatedNCT04912141Phase 2
Sponsor listed in the registry: Pharming Technologies B.V.
- Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) PatientsCompletedNCT01359969Phase 2
Sponsor listed in the registry: Pharming Technologies B.V.
- Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19CompletedNCT04530136Phase 2
Sponsor listed in the registry: Pharming Technologies B.V.
- A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial DiseaseCompletedNCT03888716Phase 1
Sponsor listed in the registry: Abliva AB · First submitted before Abliva AB became part of Pharming Group N.V.
- Drug-drug Interaction Study of KL1333 in Healthy SubjectsCompletedNCT04643249Phase 1
Sponsor listed in the registry: Abliva AB · First submitted before Abliva AB became part of Pharming Group N.V.
- A Study of the Safety and Immunogenicity of Repeated rhC1INH AdministrationCompletedNCT00851409Phase 2
Sponsor listed in the registry: Pharming Technologies B.V.
- A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 InhibitorCompletedNCT02247739Phase 2
Sponsor listed in the registry: Pharming Technologies B.V.
- Copenhagen Head Injury Ciclosporin (CHIC) StudyCompletedNCT01825044Phase 2
Sponsor listed in the registry: NeuroVive Pharmaceutical AB · First submitted before NeuroVive Pharmaceutical AB became part of Pharming Group N.V.
- Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE AttacksCompletedNCT01188564Phase 3
Sponsor listed in the registry: Pharming Technologies B.V.
- A Study to Compare the Bioavailability and Pharmacokinetics of Cyclosporine After Intravenous Administration of NEUROSTAT®, a CREMOPHOR® EL-free Lipid Emulsion, and SANDIMMUNE® Injection (a Suspension of Cyclosporine in CREMOPHOR® EL) in Healthy VolunteersCompletedNCT01692834Phase 1
Sponsor listed in the registry: NeuroVive Pharmaceutical AB · First submitted before NeuroVive Pharmaceutical AB became part of Pharming Group N.V.
- Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaCompletedNCT00261053Phase 2
Sponsor listed in the registry: Pharming Technologies B.V.
- Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaCompletedNCT00262288Phase 2/3
Sponsor listed in the registry: Pharming Technologies B.V.
- Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaCompletedNCT00225147Phase 2/3
Sponsor listed in the registry: Pharming Technologies B.V.
- Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaCompletedNCT00262301Phase 3
Sponsor listed in the registry: Pharming Technologies B.V.
- Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal TransplantationWithdrawnNCT01035593Phase 2
Sponsor listed in the registry: Pharming Technologies B.V.